Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB122 in LRRK2-Associated Parkinson’s Disease
2024-513384-15-00Phase 2Authorised
- Sponsor
- Denali Therapeutics Inc.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIIB122 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Planned start Nov 2024; status: authorised.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-513384-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513384-15-00.